PW01-036 – Renal replacement therapy in patients with FMF
نویسندگان
چکیده
منابع مشابه
PW01-036 – Renal replacement therapy in patients with FMF
Results Hemodialysis: Of the 28 patients not undergoing renal transplantation (Tx) in Armenia, 9 died (systemic amyloidosis 5, heart attack 2, stroke -2); 15 moved to another country and 4 remained on dialysis. Over half of the 25 pts with minimum observation period of 6 mo were resistant to EPO. One third died, mainly due to cardiovascular complications and systemic amyloidosis. Living related...
متن کاملPW01-012 – Canakinumab in patients with FMF
Results There were 19 patients with FMF (13 F/6 M) who were receiving canakinumab for various indications. Here we report 10 (6 F/4 M) who had at least 3 injections. Three patients had concomitant diseases such as psoriasis, ankylosing spondylitis and polyarteritis nodosa. The indications for canakinumab (150mg) were colchicine resistancy in 7 patients (>1 attack/month), amyloidosis in 2 and in...
متن کاملPW01-007 – Colchicine brand switching in FMF patients
Introduction In July of 2009 the U.S. Food and Drug Administration enacted new regulation of colchicine under the “Unapproved Drugs Program.” Like other old drugs that were on the market before the existence of the FDA, colchicine had never been subjected to FDA-required safety and efficacy trials. One company elected to put colchicine through the FDA’s approval protocol and when approval was g...
متن کاملPW01-018 – Circulating endothelial biomarkers in FMF
Methods Forty FMF patients and eighteen healthy controls with no known cardiovascular risk factors were included. All patients were receiving regular colchicine treatment and examinations were performed during attack-free periods. Serum samples were used for the determination of high sensitive C-reactive protein (hs-CRP), tissue factor (TF), tissue plasminogen activator (t-PA) and osteoproteger...
متن کاملPW01-009 – Markers of inflammation in adult FMF patients
Methods 40 consecutive patients suffering from FMF according to the Livneh criteria and 40 healthy controls (C) were included into the study in Herne, Germany. All participants were Turkish migrants aged ≥18 years. Patients were excluded if they reported symptoms of FMF ≤7 days prior to inclusion. Frequency of FMF attacks during the 3 months preceding the study inclusion was assessed. Patients ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pediatric Rheumatology
سال: 2013
ISSN: 1546-0096
DOI: 10.1186/1546-0096-11-s1-a89